BioSpace News Archive

Innate Pharma SA reported its consolidated financial results for the quarter ending March 31, 2023.

CTI BioPharma announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB, a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion.

CellFE Inc. announced the commercial availability of its Infinity Mtx™ cellular engineering platform, which uses rapid cell compression and re-expansion to actively transport a target payload into the cell.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the first patient has been dosed in Delivir, a Phase I clinical trial evaluating TG6050.

Boehringer Ingelheim and Zealand Pharma A/S announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose.

Immodulon announces it has elected Richard Davies as Chairman of the Board and appointed Gertjan Bartlema as Chief Executive Officer and Peter Greaney as Chief Business Officer.

Alvotech announced that it has entered into an exclusive agreement with Polifarma Ilac San. ve tic. A.S. for the commercialization in Turkey of AVT06, a proposed biosimilar to Eylea®.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced it will provide its inactivated COVID-19 vaccine, CoronaVac®, to self-paying groups in Hong Kong.

Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. announced that the U.S. Food and Drug Administration has approved ELFABRIO in the United States for the treatment of adult patients with Fabry disease.

Achilles Therapeutics plc announced that the Company’s new AI application, trained with proprietary real-world data, outperformed current AI and non-AI state-of-the-art methods for neoantigen immunogenicity prediction in a recent analysis, enabling the identification of the most potent clonal neoantigens for personalized cancer therapies.